
    
      Hormonal therapy with fulvestrant 500 mg to be administered before surgery With docetaxel,
      Trastuzumab, and pertuzumab to determine pathological complete remission rate at the time of
      surgery in ER-positive and HER2-positive patients with breast cancer.
    
  